uMotif, a rapidly growing player in clinical research technology, has forged a collaboration with MoCA Cognition, creators of a leading cognitive impairment detection test. Together, they aim to simplify the collection of high-quality cognitive function and eCOA/ePRO data for CNS research.
Specialising in patient-centric ePRO and capturing complex ClinRO instruments, uMotif brings unparalleled expertise to CNS studies, including those in psychedelic therapies, schizophrenia, and major depressive disorder. By partnering with MoCA Cognition, renowned for its top-ranked MoCA Test, uMotif strengthens its CNS portfolio. Developed by Dr. Ziad Nasreddine, MoCA Test is now available in over 200 languages and can be administered via tablet app or videoconference, seamlessly integrated into the uMotif platform for central rating and review.
MoCA's latest offering, XpressO, introduces a self-administered digital cognitive pre-screening tool distinguishing subjective versus objective cognitive impairment. This innovation, providing indicative scores on the standard MoCA, facilitates rapid and scalable study pre-screening.
Together, the standard MoCA and XpressO streamline eCOA/ePRO data capture alongside cognitive testing, reducing screen failure rates and accelerating study timelines. Validation against the digital MoCA test as a gold standard demonstrated a strong association between MoCA Memory Index Score (MIS) and XpressO memory task score.
Deployable solutions using the standard MoCA test and uMotif platform are readily available. Meet the uMotif team at SCOPE Summit 2024, Booth 731, to explore how they can elevate your organisation's clinical research programs.
Click here to read the original news story.